Why Illumina's GRAIL Acquisition Was Forced to Unwind — Cancer Screening vs. Antitrust
$7.1B · EU/FTC Blocked · Forced Divestiture 2024 · Liquid Biopsy · Galleri Blood Cancer Test
Background
Illumina is the global #1 in next-generation sequencing (NGS) equipment and reagents, holding approximately 80% of the sequencing market. GRAIL was a spinoff founded by Illumina itself in 2016, developing 'liquid biopsy' technology that detects circulating tumor DNA (ctDNA) in blood to enable early detection of over 50 types of cancer.
GRAIL's flagship product, the Galleri blood test, can detect 50+ cancer types from a single blood draw. Clinical studies in 2020 demonstrated positive predictive value exceeding 40%, raising hopes for revolutionizing conventional cancer screening methods. Galleri received FDA Breakthrough Device Designation in 2021.
In September 2020, Illumina announced it would re-acquire GRAIL for $7.1B, completing a vertical integration that would make Illumina the exclusive NGS sequencer supplier for GRAIL. However, the EU Commission raised antitrust concerns that Illumina could discriminate or refuse to supply sequencers to GRAIL's competitors (other liquid biopsy startups).
In 2022, the EU Commission cited Illumina for 'gun-jumping' — completing the GRAIL acquisition before receiving regulatory approval — imposing a €432M fine and ordering forced divestiture. Illumina appealed to the EU General Court but lost in September 2023. Illumina fully divested GRAIL as an independent company in 2024, ending the acquisition in complete failure.
Deal Summary
- Deal Value
- $7.1B (cash + stock, failed — forced divestiture)
- Acquirer
- Illumina, Inc.
- Target
- GRAIL, Inc.
- Announced
- September 2020
- Closed
- Forced divestiture completed 2024
- Country
- United States
Executive Summary
- $7.1B acquisition announced → acquisition completed without EU approval → EU forced divestiture order
- GRAIL: Galleri test detects 50+ cancers from blood — FDA Breakthrough Device designation
- EU Commission 'gun-jumping' violation — €432M fine + forced divestiture order
- Illumina's vertical integration strategy: NGS sequencers (80% share) + downstream liquid biopsy monopoly concerns
- September 2023 EU General Court appeal lost → GRAIL divestiture completed 2024
- Lesson: Gun-jumping (completing merger before EU approval) triggers severe EU response
Industry Overview
The liquid biopsy market is projected to grow from $5B in 2022 to over $30B by 2030, an early-stage high-growth market. MCED (Multi-Cancer Early Detection) tests capable of diagnosing multiple cancers from a single blood draw have the potential to complement and eventually replace traditional imaging-based screening. Illumina's ~80% monopoly on NGS sequencers means all liquid biopsy companies — including GRAIL's competitors — depend on Illumina sequencers.
Liquid Biopsy Market Size
$5B
2022, projected $30B+ by 2030
Illumina NGS Market Share
~80%
Global gene sequencer market
Galleri Detectable Cancer Types
50+
Single blood test
EU Fine
€432M
Gun-jumping violation
Key Players
Company Overview: GRAIL, Inc.
GRAIL was founded in 2016 with Illumina's support as a cancer early detection startup. Its core technology analyzes the methylation patterns of circulating tumor DNA (ctDNA) in blood to predict cancer type and origin. The Galleri test — which received FDA Breakthrough Device Designation in 2021 — is its flagship product.
Year Founded
2016
Illumina spinoff
Galleri Detectable Cancers
50+
Single blood test
Clinical Sensitivity
~67%
Stage I-III cancer detection
FY2021 Revenue
~$67M
Early commercialization stage
Revenue by Segment (FY2022)
Deal Structure
Illumina sought to acquire GRAIL for $7.1B in a cash and stock combination. However, Illumina completed the acquisition in August 2021 while EU Commission review was still ongoing (gun-jumping), and the EU determined this violated EC Merger Regulation, ordering a fine and forced divestiture.
Pre-Deal
Illumina, Inc.
NASDAQ: ILMN
GRAIL, Inc.
Private startup
Post-Deal
Illumina, Inc.
€432M fine, forced divestiture
GRAIL, Inc.
Re-separated as independent company 2024
Key Terms
Advisors
Illumina deployed numerous legal and lobbying advisors to respond to EU regulation but was unable to reverse the European Commission's firm stance.
Acquirer (Illumina) Advisors
Goldman Sachs
Financial Advisor (FA)Acquisition structure design
Skadden Arps
Legal Counsel (M&A)Transaction documents and regulatory response
Freshfields Bruckhaus Deringer
EU Regulatory Legal CounselEU Commission defense
Target (GRAIL) Advisors
Lazard
Financial Advisor (FA)Fairness opinion
Wilson Sonsini
Legal CounselTransaction legal support
Advisor information based on public sources.
Financials
Unit: USD million. Early commercialization loss-making company. Based on public estimates.
| Item | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Revenue | USD 12million | USD 67million | USD 125million |
| COGS | USD 50million | USD 100million | USD 130million |
| Gross Profit | USD -38million | USD -33million | USD -5million |
| SG&A | USD 200million | USD 280million | USD 310million |
| Operating Income | USD -380million | USD -560million | USD -600million |
| EBITDA | USD -360million | USD -530million | USD -570million |
| EBITDA Margin | -3000.0% | -791.0% | -456.0% |
Valuation
Despite GRAIL being in early commercialization, Illumina assigned a $7.1B valuation reflecting the transformative potential of the Galleri test and NGS sequencer vertical integration synergies.
| Metric | Value | Notes |
|---|---|---|
| Announced Acquisition Value | $7.1B | Cash + stock combination |
| GRAIL FY2021 Revenue | ~$67M | Early commercialization stage |
| EV/Revenue | ~100×+ | Reflecting pipeline value |
| EU Fine | €432M | Gun-jumping violation |
| Forced Divestiture Costs | Hundreds of millions+ | Legal fees + separation costs |
Financial metrics based on public data estimates.
Share this deal
Deal Rationale
Illumina's Acquisition Rationale
- Vertical integration completion — NGS sequencers (upstream) + GRAIL cancer diagnostics (downstream)
- Accelerate Galleri commercialization globally — leveraging Illumina's distribution and customer network
- Early mover advantage in cancer screening — capturing leadership in projected $30B+ 2030 market
- Potential to slow GRAIL competitors — competitive differentiation through sequencer access advantage
- Illumina valuation diversification — expanding from equipment/reagents to diagnostic services
GRAIL Board and Shareholder Rationale
- Illumina's global distribution network accelerates Galleri commercialization
- Cost structure optimization through integration with sequencer monopoly supplier
- $7.1B premium — high value realization for early-stage startup
- Accelerate large-scale clinical data acquisition with Illumina's capital and scale
Post-Deal Assessment (2024-12 as of)
After legal battles with the EU, Illumina fully divested GRAIL in 2024. The separated GRAIL pursued an independent NASDAQ listing. Illumina itself experienced turmoil including stock price decline and CEO change (Francis deSouza resignation). GRAIL's Galleri test continues clinical expansion as an independent company, with a UK NHS pilot study attracting significant attention.
Positives
- GRAIL: Galleri commercialization continues — NHS pilot studies and clinical expansion
- Illumina's regulatory failure served as a critical warning about gun-jumping compliance
- Raised awareness of the innovation value of liquid biopsy market
Risks & Concerns
- Illumina: $7.1B investment loss + €432M fine + hundreds of millions in legal fees
- Illumina stock crash and CEO replacement — management turmoil
- GRAIL: Post-independence financing and commercialization pace challenges
- EU's aggressive gun-jumping enforcement emerged as new risk for global M&A strategy
This announcement appears as a matter of record only
Illumina, Inc.
Acquirer
GRAIL, Inc.
Target
Attempted Acquisition → EU Forced Divestiture
Transaction Size
$7.1B (forced divestiture, EU fine €432M)
USD 7.1B (terminated by EU order)
EV / EBITDA
N/A (loss-making company)
Multiple
Closed
Divested 2024
Deal Date
Editor's Note
The Illumina-GRAIL deal teaches two key lessons. First, 'gun-jumping': completing an acquisition before EU regulatory approval is a clear violation of EU competition law, resulting in forced divestiture and substantial fines. Second, the antitrust paradox of vertical integration: Illumina's NGS sequencer monopoly (80%) was a strength, but simultaneously it was what made the GRAIL acquisition an antitrust problem. The stronger the market dominance, the more rigorous the regulatory scrutiny in M&A.
Key Concepts in This Deal
NGS sequencers (upstream) + cancer diagnostics (downstream) — vertical integration that triggered antitrust concerns
EU gun-jumping regulation: completing acquisition before approval → €432M fine + forced divestiture
Galleri blood cancer test technology acquisition + NGS ecosystem vertical integration — strategy derailed by regulation
Illumina's 80% NGS market dominance — simultaneously the source of antitrust concern in GRAIL acquisition
Frequently Asked Questions
What was the core reason the Illumina-GRAIL deal failed?
Two reasons. First, gun-jumping: Illumina completed the acquisition in August 2021 while EU Commission review was still ongoing. Under EU competition law this was a clear violation, and the EU imposed a €432M fine and ordered forced divestiture. Second, antitrust: the EU determined that combining Illumina's 80% NGS sequencer monopoly with the GRAIL acquisition could allow differential access to sequencers for other liquid biopsy startups.
What is GRAIL's Galleri test and why is it revolutionary?
Galleri is a liquid biopsy test that can simultaneously screen for over 50 types of cancer from a single blood draw. It analyzes methylation patterns in circulating tumor DNA (ctDNA) in blood to predict not just the presence of cancer but also the type and site of origin. Unlike conventional cancer screening (colonoscopy, mammography, etc.) which each target specific cancers, Galleri screens for multiple cancers from a single blood test.
What is gun-jumping and why is it problematic?
Gun-jumping refers to implementing a merger before receiving regulatory authority approval. Under EU Merger Regulation, M&A above certain size thresholds must receive prior EU Commission approval. Illumina completed the GRAIL acquisition while EU scrutiny was ongoing, and the EU determined this violated the rules, imposing the largest fine in its history (€432M). All cross-border large-scale M&A must not complete acquisitions before obtaining approval from major regulatory jurisdictions.
What happened to Illumina and GRAIL after the divestiture?
Post-divestiture, Illumina experienced a stock price decline, CEO replacement (Francis deSouza resigned), and board conflicts. Activist hedge fund Carl Icahn also pressured management changes. GRAIL pursued re-listing as an independent company while continuing clinical expansion of the Galleri test. A large-scale pilot study with the UK NHS (targeting 1.4 million people) has attracted significant attention, and the cancer early detection innovation continues.
Was this helpful?
Share it with someone
Related Deals
Sources & Notes
- [1]Illumina Press Release — Illumina Acquires GRAIL (September 2020)
- [2]EU Commission Decision — Illumina/GRAIL Merger Blocked (September 2022)
- [3]EU General Court — Judgment on Illumina Appeal (September 2023)
- [4]GRAIL — Galleri Clinical Data and FDA Breakthrough Device Designation (2021)
- [5]Bloomberg — Illumina to Divest GRAIL After EU Court Defeat (2023)
- [6]The Wall Street Journal — How Illumina's $7 Billion Bet on Cancer Testing Unraveled (2024)